Dr. Samik Basu joined Cabaletta in December 2019 and was most recently Vice President of Preclinical Research and Translational Medicine before assuming his new role as Chief Scientific Officer. Prior to joining Cabaletta, Dr. Basu was Head of Translational Sciences (Medicine) at Adaptimmune Therapeutics, Plc, where he led research efforts focused on understanding the mechanisms of resistance and response to TCR based adoptive immunotherapies to inform next generation approaches and clinical strategies. Before that, Dr. Basu co-led preclinical development efforts for Keytruda (pembrolizumab) at Merck Research Laboratories. He is a physician-scientist with 17 years of industry and academic experience in adoptive immunotherapy, translational research, autoimmunity, and tumor immunology with prior roles at the National Institutes of Health, Albert Einstein College of Medicine, and the University of Pennsylvania. Dr. Basu received his M.D. from Temple University and completed residency training in Clinical Pathology.